# OnCo record paper-maniakas-neoadjuvant-braf-atc-jama-oncol-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-maniakas-neoadjuvant-braf-atc-jama-oncol-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-maniakas-neoadjuvant-braf-atc-jama-oncol-2020" ;
  schema:name "Overall survival in anaplastic thyroid carcinoma 2000 to 2019: impact of targeted therapy and neoadjuvant BRAF-MEK inhibition"@en ;
  schema:description "At MD Anderson, survival in anaplastic thyroid cancer improved dramatically over two decades as BRAF testing, targeted therapy and neoadjuvant BRAF-MEK inhibition followed by surgery were introduced, with one-year survival rising from 35 to 59 percent."@en ;
  schema:url <https://onco.cc/key-papers/paper-maniakas-neoadjuvant-braf-atc-jama-oncol-2020/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1001/jamaoncol.2020.3362>, <https://pubmed.ncbi.nlm.nih.gov/32761153/> ;
  schema:sameAs <https://doi.org/10.1001/jamaoncol.2020.3362> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Maniakas A, Dadu R, Busaidy NL, et al." ;
  onco:cancers <https://onco.cc/cancers/anaplastic-thyroid-cancer/> ;
  onco:journals <https://onco.cc/journals/jama-oncology/> .